GlassScriptPhysician profile
Kim L Hamilton
NPI 1366513590
$988.31
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $208.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.79 | 2021-2022 | |
| Pfizer INC. | $77.33 | 2021-2022 | |
| Lilly USA, LLC | $73.60 | 2021 | |
| Glaxosmithkline, LLC. | $46.17 | 2021 | |
| Merck Sharp & Dohme LLC | $43.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $36.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $35.38 | 2021 | |
| Amarin Pharma, INC. | $34.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.08 | 2021 | |
| Amgen INC. | $30.10 | 2021 | |
| Adlon Therapeutics L.P. | $19.88 | 2021 | |
| Abbvie INC. | $18.69 | 2021 | |
| Bausch Health US, LLC | $17.35 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.98 | 2022 | |
| Cranial Technologies, INC | $14.00 | 2021 | |
| Currax Pharmaceuticals LLC | $12.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.